12 April 2016 : Original article
Intrahepatic Cholangiocarcinoma in the Liver Explant After Liver Transplantation: Histological Differentiation and Prognosis
Kazuhiro TakahashiABCDEF, Joseph ObeidB, Charlotte S. BurmeisterC, David A. BrunoE, Marwan M. KazimiE, Atsushi YoshidaE, Marwan S. AbouljoudDEG, Gabriel T. SchnickelABDEFGDOI: 10.12659/AOT.895936
Ann Transplant 2016; 21:208-215
Abstract
BACKGROUND: The aim of this study was to evaluate the outcome of patients with intrahepatic cholangiocarcinoma (ICCA) incidentally found in the explanted liver after liver transplantation.
MATERIAL AND METHODS: We retrospectively reviewed 1188 recipients undergoing liver transplantation from August 2003 to August 2014; 13 patients were found to have ICCA (1.1%). Recurrence-free survival (RFS) rate was compared between ICCA patients and the matched cohort of 39 patients with hepatocellular carcinoma (HCC). We also investigate the relevance of clinical and pathological parameters in recurrence of ICCA.
RESULTS: ICCA patients showed significantly higher recurrence rate with lower 1-year and 3-year RFS rates than HCC patients (recurrence rate, 12.8% vs. 54.8%; 1-year and 3-year RFS rates, 94% and 84% vs. 67% and 42%). Of the 13 ICCA patients, 4 were diagnosed with a well-differentiated ICCA and 9 with a moderately-differentiated ICCA. There was no recurrence among those with a well-differentiated ICCA, whereas 78% recurred in the moderately-differentiated group. The median RFS time for the moderately-differentiated group was 13.0 months, yielding RFS rates of 56% at 1 year and 22% at 3 years.
CONCLUSIONS: Liver transplantation in patients with a well-differentiated ICCA yielded excellent outcomes as compared to patients with a moderately-differentiated ICCA. This may allow consideration of transplantation in the setting of a well-differentiated ICCA, and obviate the need for adjuvant systemic treatment. Conversely, a moderately-differentiated ICCA carries a poor prognosis with a prohibitively high recurrence rate and poor survival. Liver transplantation should remain a contraindication in this group.
Keywords: Bile Ducts, Intrahepatic, Cholangiocarcinoma, Liver Transplantation, Neoplasms by Histologic Type
In Press
Original article
Common Versus External Iliac Arterial Anastomosis in Kidney Transplantation: A Bicentric Retrospective Anal...Ann Transplant In Press; DOI: 10.12659/AOT.953269
Original article
Protective Effects of Quercetin and Sucrose on Cold Preservation Injury in Porcine Kidneys Donated After Ca...Ann Transplant In Press; DOI: 10.12659/AOT.952503
Original article
Four Years of Clinical Experience With COVID-19 Outcomes in Heart Transplant RecipientsAnn Transplant In Press; DOI: 10.12659/AOT.952888
Original article
Determinants of Lack of Consent for Deceased Organ Donation Among Nurses and Physicians: A Cross-Sectional ...Ann Transplant In Press; DOI: 10.12659/AOT.953598
Most Viewed Current Articles
24 Aug 2021 : Review article 21,160
Normothermic Machine Perfusion (NMP) of the Liver – Current Status and Future PerspectivesDOI :10.12659/AOT.931664
Ann Transplant 2021; 26:e931664
29 Dec 2021 : Original article 17,335
Efficacy and Safety of Tacrolimus-Based Maintenance Regimens in De Novo Kidney Transplant Recipients: A Sys...DOI :10.12659/AOT.933588
Ann Transplant 2021; 26:e933588
22 Nov 2022 : Original article 16,325
Long-Term Effects of Everolimus-Facilitated Tacrolimus Reduction in Living-Donor Liver Transplant Recipient...DOI :10.12659/AOT.937988
Ann Transplant 2022; 27:e937988
05 Apr 2022 : Original article 16,249
Impact of Statins on Hepatocellular Carcinoma Recurrence After Living-Donor Liver TransplantationDOI :10.12659/AOT.935604
Ann Transplant 2022; 27:e935604






